CN - Dupilumab
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| S-002415/24 | 14. 10. 2024 | Sanofi s.r.o. | 8 114 513,34 | 7 245 101,20 | 8 114 513,34 | 7 245 101,20 | CZK | |
| 2151/2024-SML | 22. 10. 2024 | Sanofi s.r.o. | 24 696 344,96 | 22 050 308,00 | 24 696 344,96 | 22 050 308,00 | CZK | |
| 2-141/2024-1470 | 11. 10. 2024 | Sanofi s.r.o. | 16 934 636,54 | 15 120 211,20 | 16 934 636,54 | 15 120 211,20 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| 01_Písemná zpráva zadavatele_Dupilumab_EP.pdf | Písemná zpráva zadavatele | 29. 10. 2024 07:14 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| Sanofi s.r.o. | Praha | 49 745 494,85 | 44 415 620,40 | CZK | Yes |